- Solid Tumors
- Pipeline Molecules
- Alliance Partners
Our mission is to provide healthcare professionals with unbiased clinical research information, easily.
Currently, you can access the following clinical trials being conducted worldwide:
Proposed Mechanism of Action
Ozanimod is an oral, sphingosine-1-phosphate (S1P) receptor modulator that binds with high affinity selectively to S1P subtypes 1 (S1P1) and 5 (S1P5). The exact mechanism by which ozanimod exerts its therapeutic action is unknown. Preclinical data showed that ozanimod was able to induce internalization of the S1P1 receptor and decrease circulation of pro-inflammatory lymphocytes in the bloodstream. A reduction in circulating pro-inflammatory lymphocytes may prevent their migration to sites of inflammation. Preclinical data have also demonstrated that ozanimod treatment results in a dose-dependent reduction in key lymphocyte populations that play a role in inflammatory bowel disease (IBD).1 These results may support the hypothesis that S1P1 is a potential new target for IBD treatment.
Ozanimod Proposed Mechanism of Action
Ozanimod, an S1P1 and S1P5 ?modulator is hypothesized to prevent migration of lymphocytes from the lymphoid tissue to the gastrointestinal tract1